DMK Pharmaceuticals (LTS:0A4X) Total Payout Ratio : 0.00 (As of Jun. 10, 2024)

View and export this data going back to 2020. Start your Free Trial

What is DMK Pharmaceuticals Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

DMK Pharmaceuticals's current Total Payout Ratio is 0.00.

DMK Pharmaceuticals Total Payout Ratio Historical Data

The historical data trend for DMK Pharmaceuticals's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Total Payout Ratio Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Payout Ratio

Get a 7-Day Free Trial

0.96

0.50

0.37

1.13

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of DMK Pharmaceuticals's Total Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals's Total Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Total Payout Ratio falls into.

DMK Pharmaceuticals Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

DMK Pharmaceuticals's Total Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-26.478
	=	0.00

DMK Pharmaceuticals's Total Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-1.388
	=	0.00

DMK Pharmaceuticals Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (LTS:0A4X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (LTS:0A4X) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

DMK:USA

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (LTS:0A4X) Headlines

No Headlines